Adenoid Cystic Carcinoma Market According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 08/Jul 19:16
Bladder Cancer Pipeline 2024 | UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology Inc., Ferring Pharma
DelveInsight’s, “Bladder Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and
Articles similaires
KEYTRUDA (pembrolizumab) injection, powder, lyophilized, for solution KEYTRUDA (pembrolizumab) injection, solution [Merck Sharp & Dohme LLC ]
nlm.nih.gov - 06/Aug 04:00
Updated Date: Tue, 06 Aug 2024 00:00:00 EDT
KEYTRUDA (pembrolizumab) injection, powder, lyophilized, for solution KEYTRUDA (pembrolizumab) injection, solution [Merck Sharp & Dohme LLC ]
nlm.nih.gov - 16/Aug 04:00
Updated Date: Fri, 16 Aug 2024 00:00:00 EDT
Stanford University (US): Cancer Clinical Research Coordinator Associate - Radiation Oncology
pharmiweb.com - 00:00
Competitive: Stanford University (US): Cancer Clinical Research Coordinator Associate - Radiation Oncology (Hybrid) The Stanford Cancer Institute...
PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial
thedeepdive.ca - 13:08
Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study...
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com - 13/Aug 13:15
Urogen Pharma (URGN) delivered earnings and revenue surprises of -10.98% and 7.76%, respectively, for the quarter ended June 2024. Do the numbers hold...
Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome
drugs.com - 15/Aug 00:08
MELBOURNE, Australia, Aug. 14, 2024. Prota Therapeutics Pty Ltd (Prota), an Australian clinical-stage biotechnology company focused on the development...
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
drugs.com - 08/Aug 06:08
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering...
Explore the BCG's Bladder Cancer-Fighting Mechanisms
medindia.net - 11/Aug 23:18
Novel zebrafish model has helped researchers discover the immune mechanisms that make Bacillus Calmette-Guerin (BCG) effective against bladder...
Les derniers communiqués
-
Aucun élément